Promomed plans to enter the Iraqi market

Promomed Group's production site in Saransk has successfully passed the international audit of the Ministry of Health of the Republic of Iraq according to GMP standards, which opens the company's entrance to the Middle East market. A wide range of neurological, antitumor, antibacterial, anti-inflammatory and other drugs is planned for registration and further circulation in Iraq. It includes about 300 positions of drugs in various forms, names and dosages.